Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > I know a sale when i see one :-) Keep the faith
View:
Post by Oden6570 on Dec 16, 2023 9:00am

I know a sale when i see one :-) Keep the faith

 TLD1433

TLD1433 (also known as Ruvidar® and “Theralase®) was the first Ru(II)-based photosensitizer to enter clinical trials and successfully complete a phase 1b human clinical trial (NCT03053635). A phase 2 study is ongoing (NCT03945162) [114,115] to evaluate TLD1433 in non-muscle-invasive bladder cancer patients. It has been recently suggested as a repositioning drug for the treatment of conjunctival melanoma, which is a rare but often deadly ocular cancer [116], and human lung adenocarcinoma [117]. Recently, Karges (2022) [118] reviewed the clinical development of TLD1433 and other metal-containing compounds, including rostaporfin (Purlytin®), motexafin lutetium (Lutrin®/Antrin®), and the sulfonated aluminium phthalocyanin (Photosens®), bearing the different metals Sn, Lu, and Al, respectively, as well as padeliporfin (WST09) and padeliporfin (WST11 or TOOKAD® soluble), which contain Pd, as photosensitizers for the photodynamic therapy of cancer.

Pharmaceuticals | Free Full-Text | Complexes of Ruthenium(II) as Promising Dual-Active Agents against Cancer and Viral Infections (mdpi.com)
Comment by Oden6570 on Dec 16, 2023 9:16am
Anyone have knowledge of what a repositioning drug is ? Thanks in advance. 
Comment by 99942Apophis on Dec 16, 2023 9:59am
Drug repositioning, also referred to as drug repurposing or drug reprofiling, is the process of uncovering new indications of the approved or failed/abandoned compounds for use in a different disease 
Comment by Alamir1111 on Dec 16, 2023 10:22am
That is exactly what Google said. The article  talks about 8 different cancers where ru could be useful. and the effectiveness on viruses covid  Sars etc like every study, scientists praise the compound efficiency .But at the end is always that there needs to be more studies tests  research done.Ruvidar is kind of like the Swiss knife. That would be my basic understanding of that ...more  
Comment by Alamir1111 on Dec 16, 2023 10:49am
According to Google Aspirin is one of the oldest example of repositioning.  Originally invented as a pain killer later on used in low dosage as a prevention of heart attacks. 
Comment by Alamir1111 on Dec 16, 2023 2:14pm
Oden seems to me that you have an interst on covid front .If I remember correctly  there was an article a while ago U of Guelph ontario doing some research on animals to see if they can prevent them getting  covid .using tld..Maybe got time to do some digging?
Comment by Oilminerdeluxe on Dec 16, 2023 3:14pm
Maybe Dr. Coombs has some insights.He has an e-mail somewhere. Last time I was in contact with him, he was not totally out of the loop of things. But if they are trying to save money, perhaps not much has happened.
Comment by Pandora on Dec 16, 2023 3:34pm
https://www.uoguelph.ca/research/article/susceptibility-pets-sars-cov-2
Comment by Longholder99 on Dec 17, 2023 12:53pm
The value of the patent Theralase holds on Ruthenium and TLD1433 is becoming more apparent on a global scale. Once FDA approves it for BTD and AA the multi indication use will be huge.  Market Cap will start with a B and who knows how many multiples. Just IMO. 
Comment by Oilminerdeluxe on Dec 17, 2023 2:13pm
B is a nice letter. 
Comment by Alamir1111 on Dec 17, 2023 3:06pm
Sounds good Monday I should get an order in for an Audi rs6
Comment by Alamir1111 on Dec 17, 2023 3:45pm
Mind you at today's price it is 1.005.000 shares
Comment by Alamir1111 on Dec 17, 2023 4:15pm
Guess for Christmas Yer up yor yer kilt
Comment by DeathXray33 on Dec 18, 2023 1:31pm
I bought more today... I like buying 2x a week...
Comment by chry200030 on Dec 18, 2023 1:35pm
Yah.. at this price it's a no brainer.   
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250